Onderzoeker
Betty Willems
Publicaties
1 - 10 van 14
- Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults(2023)
Auteurs: Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Daphnée Georges, Sarah Houben, Véronique Olislagers, Alexandra Waegemans, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, et al.
Pagina's: 2829-2836 - Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients(2022)
Auteurs: Lorenzo Canti, Kevin Ariën, Isabelle Desombere, Stephanie Humblet-Baron, Pieter Pannus, L Heyndrickx, Aurelie Henry, Sophie Servais, Evelyne Willems, Gregory Ehx, et al.
Pagina's: 335-337 - Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial(2022)
Auteurs: Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y. Neven, L Heyndrickx, J Michiels, B Willems, Stéphane De Craeye, Antoine Francotte, et al.
Pagina's: e0001308 - Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant(2022)
Auteurs: Kevin Ariën, L Heyndrickx, J Michiels, K Vereecken, Kurt Van Lent, S Coppens, B Willems, Pieter Pannus, Geert A Martens, Marjan Van Esbroeck, et al.
- Third-dose BNT162b2 vaccine is highly efficient at increasing anti-rbd sars-cov-2 igg titers in allo-hct recipients(2022)
Auteurs: Lorenzo Canti, Stephanie Humblet-Baron, I Desombere, P. Pannus, Aurelie Henry, Sophie Servais, B Willems, Kevin Ariën, Yves Beguin, Maria E. Goossens, et al.
Pagina's: 280-280 - Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients(2021)
Auteurs: Lorenzo Canti, Stephanie Humblet-Baron, Isabelle Desombere, Julika Neumann, Pieter Pannus, L Heyndrickx, Aurelie Henry, Sophie Servais, Evelyne Willems, Gregory Ehx, et al.
- In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8(+) T cells in treated HIV-positive patients(2019)
Auteurs: Pieter Pannus, Philipp Alexander Adams, B Willems, L Heyndrickx, Eric Florence, Sofie Rutsaert, Ward De Spiegelaere, Linos Vandekerckhove, Carole Seguin-Devaux, G Vanham
Pagina's: 387-398 - Risk of misinterpretation of Ebola virus PCR results after rVSV ZEBOV-GP vaccination [letter](2015)
Auteurs: Lieselotte Cnops, Michèle Gerard, Olivier Vandenberg, Sigi Van den Wijngaert, L Heyndrickx, B Willems, Kathy Demeulemeester, Hilde De Clerck, Anne Dediste, Steven Callens, et al.
Pagina's: 1725-1726 - The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody(2013)
Auteurs: SS Balla-Jhagjhoorsingh, D. Corti, L Heyndrickx, B Willems, K Vereecken, D. Davis, G Vanham
Pagina's: e68863 - International network for comparison of HIV neutralization assays: the NeutNet report II(2012)
Auteurs: L Heyndrickx, A Heath, J. Sheik-Khalil, J Alcami, V. Bongertz, M. Jansson, M. Malnati, D Montefiori, C Moog, L. Morris, et al.